Gateway Investment Advisers’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-3,512
| Closed | -$248K | – | 480 |
|
|
2025
Q1 | $248K | Sell |
3,512
-1,003
| -22% | -$67.5K | ﹤0.01% | 463 |
|
|
2024
Q4 | $297K | Buy |
4,515
+66
| +1% | +$4.42K | ﹤0.01% | 441 |
|
|
2024
Q3 | $313K | Sell |
4,449
-8,222
| -65% | -$687K | ﹤0.01% | 444 |
|
|
2024
Q2 | $1.04M | Sell |
12,671
-8,649
| -41% | -$720K | 0.01% | 315 |
|
|
2024
Q1 | $1.86M | Buy |
21,320
+8,415
| +65% | +$753K | 0.02% | 282 |
|
|
2023
Q4 | $1.24M | Hold |
12,905
| – | – | 0.01% | 304 |
|
|
2023
Q3 | $1.14M | Sell |
12,905
-163
| -1% | -$14.5K | 0.01% | 303 |
|
|
2023
Q2 | $1.13M | Sell |
13,068
-24,215
| -65% | -$2.28M | 0.01% | 308 |
|
|
2023
Q1 | $3.63M | Sell |
37,283
-426
| -1% | -$44.2K | 0.04% | 241 |
|
|
2022
Q4 | $3.9M | Sell |
37,709
-74
| -0.2% | -$6.95K | 0.05% | 241 |
|
|
2022
Q3 | $3.2M | Buy |
37,783
+20
| +0.1% | +$1.78K | 0.04% | 265 |
|
|
2022
Q2 | $3.13M | Buy |
37,763
+1,134
| +3% | +$90.3K | 0.04% | 277 |
|
|
2022
Q1 | $2.82M | Buy |
36,629
+26,434
| +259% | +$2.21M | 0.03% | 303 |
|
|
2021
Q4 | $901K | Buy |
10,195
+197
| +2% | +$16.3K | 0.01% | 349 |
|
|
2021
Q3 | $773K | Sell |
9,998
-57
| -0.6% | -$4.5K | 0.01% | 370 |
|
|
2021
Q2 | $839K | Sell |
10,055
-110
| -1% | -$8.72K | 0.01% | 374 |
|
|
2021
Q1 | $768K | Sell |
10,165
-166
| -2% | -$13.6K | 0.01% | 375 |
|
|
2020
Q4 | $906K | Buy |
10,331
+20
| +0.2% | +$1.59K | 0.01% | 364 |
|
|
2020
Q3 | $784K | Sell |
10,311
-101
| -1% | -$10.2K | 0.01% | 366 |
|
|
2020
Q2 | $1.28M | Sell |
10,412
-34
| -0.3% | -$3.38K | 0.02% | 349 |
|
|
2020
Q1 | $883K | Sell |
10,446
-3,261
| -24% | -$281K | 0.01% | 366 |
|
|
2019
Q4 | $1.16M | Sell |
13,707
-5,868
| -30% | -$443K | 0.01% | 378 |
|
|
2019
Q3 | $1.32M | Sell |
19,575
-25
| -0.1% | -$1.93K | 0.01% | 383 |
|
|
2019
Q2 | $1.68M | Sell |
19,600
-97
| -0.5% | -$8.3K | 0.02% | 382 |
|
|
2019
Q1 | $1.75M | Buy |
19,697
+53
| +0.3% | +$4.91K | 0.02% | 376 |
|
|
2018
Q4 | $1.67M | Buy |
19,644
+5,772
| +42% | +$549K | 0.02% | 386 |
|
|
2018
Q3 | $1.34M | Sell |
13,872
-36
| -0.3% | -$3.59K | 0.01% | 421 |
|
|
2018
Q2 | $1.31M | Sell |
13,908
-40
| -0.3% | -$3.5K | 0.01% | 421 |
|
|
2018
Q1 | $1.13M | Buy |
13,948
+4,269
| +44% | +$366K | 0.01% | 455 |
|
|
2017
Q4 | $863K | Buy |
+9,679
| New | +$842K | 0.01% | 515 |
|
|
2015
Q3 | – | Sell |
-2,002
| Closed | -$274K | – | 648 |
|
|
2015
Q2 | $274K | Buy |
+2,002
| New | +$248K | ﹤0.01% | 634 |
|
Other funds holding BMRN
Gateway Investment Advisers's BMRN Position: Q2 2025 in Review
Gateway Investment Advisers sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2025, closing a stake of 3,512 shares — an estimated $248K sold.
Gateway Investment Advisers first reported a position in BMRN in Q2 2015 and held it in 31 quarters. The position peaked at $3.9M in Q4 2022. 581 funds tracked by Wall St. Rank hold BMRN as of Q2 2025.
- Gateway Investment Advisers reported no remaining BioMarin Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
- Gateway Investment Advisers sold 3,512 BioMarin Pharmaceuticals shares in Q2 2025, an estimated $248K.
- Gateway Investment Advisers first reported a position in BioMarin Pharmaceuticals in Q2 2015 and held it in 31 quarters.
- Gateway Investment Advisers's BioMarin Pharmaceuticals position peaked at $3.9M in Q4 2022.
- 581 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2025.
Based on Gateway Investment Advisers's 13F filing for Q2 2025, filed 9 Jul 2025.